Combination Chemotherapy and Denileukin Diftitox in Treating Patients With Newly Diagnosed T-Cell Non-Hodgkin Lymphoma
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer
cells, either by killing the cells or by stopping them from dividing. Combinations of
biological substances in denileukin diftitox may be able to carry cancer-killing substances
directly to non-Hodgkin lymphoma cells. Giving combination chemotherapy together with
denileukin diftitox may kill more cancer cells.
PURPOSE: This clinical trial is studying how well giving combination chemotherapy together
with denileukin diftitox works in treating patients with newly diagnosed T-cell non-Hodgkin
lymphoma.